Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot

被引:0
|
作者
Iwama, Eimei [1 ]
Fujimura, Taku [1 ]
Kusakari, Yoshiyuki [1 ]
Haga, Takahiro [1 ]
Aiba, Setsuya [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan
来源
CASE REPORTS IN DERMATOLOGY | 2015年 / 7卷 / 03期
关键词
Malignant melanoma in situ; BRAF(V600E) mutation; PD-L1;
D O I
10.1159/000441601
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Melanoma is an aggressive skin cancer that originates from melanocytes, and about one half of melanoma cases possess a BRAF mutation. Together with PD-L1 expression, the BRAF(V600E) mutation is one of the optimal therapeutic targets for the treatment of melanoma. In this report, we describe a case of multifocal melanoma in situ on the foot, which carried the p.V600E mutation in the BRAF gene. Interestingly, the spotted melanoma lesion is demarcated by normal skin, and in all spotted pigmented lesions, there were no signs of dermal invasion of melanoma cells or spontaneous regression. Our case presented atypical clinical features, which might correlate with the local mutations of BRAF gene and the immunological expression of PD-L1. (C) 2015 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:322 / 327
页数:6
相关论文
共 50 条
  • [21] Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
    Chong Sun
    Liqin Wang
    Sidong Huang
    Guus J. J. E. Heynen
    Anirudh Prahallad
    Caroline Robert
    John Haanen
    Christian Blank
    Jelle Wesseling
    Stefan M. Willems
    Davide Zecchin
    Sebastijan Hobor
    Prashanth K. Bajpe
    Cor Lieftink
    Christina Mateus
    Stephan Vagner
    Wipawadee Grernrum
    Ingrid Hofland
    Andreas Schlicker
    Lodewyk F. A. Wessels
    Roderick L. Beijersbergen
    Alberto Bardelli
    Federica Di Nicolantonio
    Alexander M. M. Eggermont
    Rene Bernards
    Nature, 2014, 508 : 118 - 122
  • [22] A role for immunohistochemical detection of BRAF V600E in metastatic melanoma?
    Lade-Keller, J.
    Kristensen, L. S.
    Riber-Hansen, R.
    Guldberg, P.
    Hansen, L. L.
    Steiniche, T.
    Hager, H.
    APMIS, 2013, 121 : 7 - 7
  • [23] Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
    Sun, Chong
    Wang, Liqin
    Huang, Sidong
    Heynen, Guus J. J. E.
    Prahallad, Anirudh
    Robert, Caroline
    Haanen, John
    Blank, Christian
    Wesseling, Jelle
    Willems, Stefan M.
    Zecchin, Davide
    Hobor, Sebastijan
    Bajpe, Prashanth K.
    Lieftink, Cor
    Mateus, Christina
    Vagner, Stephan
    Grernrum, Wipawadee
    Hofland, Ingrid
    Schlicker, Andreas
    Wessels, Lodewyk F. A.
    Beijersbergen, Roderick L.
    Bardelli, Alberto
    Di Nicolantonio, Federica
    Eggermont, Alexander M. M.
    Bernards, Rene
    NATURE, 2014, 508 (7494) : 118 - +
  • [24] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
    Chapman, Paul B.
    Hauschild, Axel
    Robert, Caroline
    Haanen, John B.
    Ascierto, Paolo
    Larkin, James
    Dummer, Reinhard
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Hogg, David
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    Ribas, Antoni
    O'Day, Steven J.
    Sosman, Jeffrey A.
    Kirkwood, John M.
    Eggermont, Alexander M. M.
    Dreno, Brigitte
    Nolop, Keith
    Li, Jiang
    Nelson, Betty
    Hou, Jeannie
    Lee, Richard J.
    Flaherty, Keith T.
    McArthur, Grant A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26): : 2507 - 2516
  • [25] Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma
    Thiel, Alexandra
    Moza, Monica
    Kytola, Soili
    Orpana, Arto
    Jahkola, Tiina
    Hernberg, Micaela
    Virolainen, Susanna
    Ristimaki, Ari
    HUMAN PATHOLOGY, 2015, 46 (02) : 169 - 175
  • [26] Braf V600E mutation in melanoma: translational current scenario
    J. A. Guadarrama-Orozco
    A. Ortega-Gómez
    E. B. Ruiz-García
    H. Astudillo-de la Vega
    A. Meneses-García
    C. Lopez-Camarillo
    Clinical and Translational Oncology, 2016, 18 : 863 - 871
  • [27] The BRAF V600K Mutation Is More Frequent than the BRAF V600E Mutation in Melanoma In Situ of Lentigo Maligna Type
    Stadehneyer, Eike
    Heitzer, Ellen
    Resel, Margit
    Cerroni, Lorenzo
    Wolf, Peter
    Dandachi, Nadia
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (02) : 548 - 550
  • [28] A rare pitfall in the molecular interpretation of BRAF V600E status in melanoma in the setting of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Johnstone, Kate J.
    Strutton, Geoffrey M.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2019, 46 (06) : 455 - 456
  • [29] V600E BRAF Mutation in Vulvovaginal Melanoma Is Rare: A Study of Anti-Human BRAF V600E Monoclonal Antibody in 24 Cases
    Ramineni, M.
    Malpica, A.
    Luthra, R.
    Deavers, M. T.
    Euscher, E. D.
    MODERN PATHOLOGY, 2013, 26 : 293A - 293A
  • [30] The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma
    Amaral, Teresa
    Nouri, Noura
    Garbe, Claus
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (07) : 705 - 715